LATEST RESEARCH

Research

Independent analysis of SEC filings, private funds, RIAs, websites and regulatory records.

iCapital Menlo Ventures AI & Inflection Access SEC Review: $35.8M Raised and Two-Layer Fund Risks
INDEPENDENT RESEARCH

iCapital Menlo Ventures AI & Inflection Access SEC Review: $35.8M Raised and Two-Layer Fund Risks

iCapital-Menlo Ventures AI & Inflection Access Fund, L.P. is a Delaware private equity access vehicle associated with iCapital and the Menlo Ventures investment platform. Its September 24, 2026 Form D amendment reports $35.795 million in cumulative securities sales, following an initial September 2025 filing that reported no completed sales. The offering provides a distinct route into private-market investment strategies associated with Menlo's artificial intelligence and growth-stage technology activities. However, the fund is legally separate from Menlo's flagship partnerships, and its reported capital cannot be treated as direct ownership of individual AI companies or as a proportionate share of Menlo's broader fundraising. The principal investment concern is the economic structure between the access partnership, any underlying investment vehicles and the operating companies ultimately receiving capital. Investors must establish how subscriptions are allocated, whether fees are charged at multiple levels and which valuations determine their partnership interests. The SEC filing establishes reported private fundraising activity but does not disclose a complete investment portfolio, independently verified net returns or guaranteed access to specific Menlo investments.

iCapital-Menlo Ventures AI & Inflection Access Fund, L.P. · CIK 0002087008Read article →
Genesis Fund Corp SEC Review 2026: $50M Offering, Government Leases and Investor Risks
INDEPENDENT RESEARCH

Genesis Fund Corp SEC Review 2026: $50M Offering, Government Leases and Investor Risks

Genesis Fund Corp is a Michigan corporation associated with Genesis Financial Group and a private real estate investment offering focused on commercial properties leased to United States federal government agencies. Its SEC filing history, identifiable management and publicly available private placement documentation provide a substantial foundation for independent investigation. However, the investment proposition contains several issues that deserve significantly more attention than the headline $50 million offering and government-tenant narrative. The company's promotional materials describe long-term federal leases, quarterly dividends, income generated from government-occupied properties and potential tax advantages for qualified foreign pension investors. These characteristics may support the underlying investment strategy, but they do not establish that investor principal is guaranteed by the United States government or that dividends will remain available under all circumstances. Genesis Fund Corp also should not be confused with the broader Genesis Financial organization or the separately described Genesis General Partnership Fund. Its September 2026 Form D amendment establishes continuing securities-filing activity, but the available amendment tracking information does not independently establish current consolidated assets, net operating income or the complete amount available for distribution. Investors should examine property ownership, lease documentation, debt obligations, fund expenses and the legal rights attached to the actual securities being offered. The central concern is whether the investment's advertised government-lease characteristics translate into enforceable investor protections, sustainable cash distributions and a practical exit mechanism.

Genesis Fund Corp · CIK 0001984626Read article →
SEC VERIFYINDEPENDENT
RESEARCH
SEC Filings · Verification · Analysis
INDEPENDENT RESEARCH

Contrail Hospitality Investors I SEC Review: $1.55M Filing and Hotel Investment Transparency

Contrail Hospitality Investors I LLC is a newly reported private securities issuer whose September 24, 2026 Form D is associated with approximately $1.55 million in securities sales. The entity's name indicates a hospitality-oriented investment vehicle, but the available public records do not independently establish which hotel properties, operating businesses or contractual interests it owns. This distinction is particularly important for hospitality investments because direct hotel ownership, participation in a property acquisition and investment in a hotel operating company can produce substantially different financial outcomes. The reported securities sales provide evidence of private capital activity, but they do not establish completed property acquisitions, stabilized operating income or a verified investment valuation. The main concern is the limited visibility into the relationship between investor capital and the underlying hospitality assets. Without a documented property schedule, operating statements and financing structure, investors cannot determine whether the offering is supported by an existing income-producing business or depends primarily on future acquisitions and operational improvements. The September filing therefore provides a regulatory starting point rather than sufficient evidence of financial performance.

Contrail Hospitality Investors I LLCRead article →
Risk Managed Closed End Funds SEC Review 2026: Fundraising, Andrew Sterge and Portfolio Risks
INDEPENDENT RESEARCH

Risk Managed Closed End Funds SEC Review 2026: Fundraising, Andrew Sterge and Portfolio Risks

Risk Managed Closed End Funds, L.P. is an established Delaware private investment partnership associated with Andrew J. Sterge and the Closed End Trading investment management platform. Its September 24, 2026 Form D amendment reports approximately $1 million in incremental securities sales, extending a filing history that began in October 2021. Unlike a newly organized investment vehicle with no identifiable operating background, this fund has several years of regulatory disclosures, a traceable investment manager and an identifiable relationship with an offshore investment structure. Its name indicates a closed-end fund investment focus, while its management background provides additional context concerning quantitative investment and risk management. Nevertheless, the existence of an experienced portfolio manager does not establish that the fund has consistently generated positive investment returns or successfully protected capital during market stress. The public offering records do not provide a complete audited performance history, current portfolio composition or investor-level return calculation. The principal concern is whether the fund's risk management framework can adequately address market volatility, leverage, liquidity and valuation changes while preserving returns after expenses. Investors should distinguish the manager's professional history from the independently verified financial performance of this particular partnership.

Risk Managed Closed End Funds, L.P. · CIK 0001874155Read article →
Foreword Capital Offshore Fund SEC Review: $95M Raise, Stressed Credit and Liquidity Risks
INDEPENDENT RESEARCH

Foreword Capital Offshore Fund SEC Review: $95M Raise, Stressed Credit and Liquidity Risks

Foreword Capital Offshore Fund, LP is a Cayman Islands hedge fund associated with Foreword Capital, an investment management organization founded by Alex Lerner. Unlike a newly disclosed vehicle without an operating history, Foreword began accepting investment capital in July 2024 and has accumulated a multiyear SEC filing record. Its June 2025 Form D/A reported $5.25 million in securities sold to two investors, while the September 2026 filing summary indicates that reported sales subsequently reached $95 million across six investors. The investment strategy is distinguishable from conventional diversified equity investing: independent institutional materials describe an opportunistic approach focused on stressed credit, event-driven situations and securities affected by technical or fundamental dislocations. Importantly, Foreword's existence and investment activity are supported by more than its own offering notices. Public financial statements from North Square Evanston Multi-Alpha Fund identify a real investment in the offshore vehicle and disclose its reported valuation and liquidity terms. These records provide stronger external evidence than a sponsor's marketing description alone. Nevertheless, substantial fundraising and institutional participation do not independently establish consistent performance, complete portfolio transparency or protection against investment losses. The principal concerns involve stressed-credit valuation, investor concentration, management and performance compensation, related fund arrangements and the ability to realize assets during market disruption.

Foreword Capital Offshore Fund, LP · CIK 0002028563Read article →
Bronte Capital Callisto Fund SEC Review: $213.9M Raise, Short-Selling Risks and Fees
INDEPENDENT RESEARCH

Bronte Capital Callisto Fund SEC Review: $213.9M Raise, Short-Selling Risks and Fees

Bronte Capital Callisto Fund LLC is an established Delaware hedge fund associated with Bronte Capital, the Sydney-based global long/short investment manager founded by John Hempton and Simon Maher. Its September 23, 2026 amended Form D reports $213.89 million in cumulative securities sales to 84 investors, with a $500,000 minimum investment and a first sale dating to October 2010. The filing therefore represents the continuation of a longstanding investment vehicle rather than a newly launched fund. A particularly important finding concerns its legal history: earlier SEC filings identify the issuer as Bronte Capital Callisto Fund L.P., while subsequent filings use the LLC structure under the same CIK. Its investment model also introduces material risks because Bronte's own disclosures acknowledge short selling, derivatives, margin trading and potentially concentrated portfolios. The latest Form D identifies a securities intermediary, historical estimated finders' fees and an arrangement under which the manager receives investment management fees and a special profit allocation. These disclosures establish concrete questions about investment economics, entity continuity, leverage, valuation and liquidity. The available evidence does not establish fraud or regulatory misconduct, but investors should not substitute Bronte's broader investment history for independently verified Callisto-specific financial results.

Bronte Capital Callisto Fund LLC · CIK 0001497839Read article →
Court Square AUS Co-Invest SEC Review: New Form D, Fund V and Investment Risks
INDEPENDENT RESEARCH

Court Square AUS Co-Invest SEC Review: New Form D, Fund V and Investment Risks

Court Square Capital Partners AUS Co-Invest, L.P. is a Delaware private equity investment vehicle associated with Court Square Capital Partners, an established New York investment firm focused on middle-market businesses. Its September 24, 2026 Form D identifies a new co-investment offering under CIK 0002154673, with no securities sold and an indefinite offering amount reported at the initial filing date. The vehicle emerges during a period of substantial fundraising activity for the broader sponsor, which announced the closing of its fifth flagship fund at approximately $3.8 billion in April 2026. However, the financial scale and historical operating experience of Court Square should not be confused with the actual investment economics of AUS Co-Invest. The new issuer is a separate legal vehicle whose public filing does not independently establish its underlying acquisition target, purchase valuation, ownership percentage or eventual investor distributions. The central concern is therefore the distinction between sponsor-level credibility and transaction-level transparency. Investors should examine the individual partnership's assets, contractual rights and relationship with affiliated Court Square funds before treating the broader manager's investment history as evidence of performance or financial strength attributable to this particular offering.

Court Square Capital Partners AUS Co-Invest, L.P. · CIK 0002154673Read article →
Baillie Gifford Private Growth Opportunity Fund SEC Review: Zero Sales, Valuation and Investor Risks
INDEPENDENT RESEARCH

Baillie Gifford Private Growth Opportunity Fund SEC Review: Zero Sales, Valuation and Investor Risks

Baillie Gifford Private Growth Opportunity Fund (No. 1) L.P. is a newly organized Cayman Islands private equity vehicle associated with the established Baillie Gifford investment management group. Its September 23, 2026 SEC Form D establishes an identifiable investment manager, legal structure and proposed private offering, but reports zero investors, zero securities sold and an indefinite offering amount, with the first sale yet to occur. A particularly important finding is the issuer's previous name, Baillie Gifford Co-Invest (No. 8) Fund LP, which appears under the same CIK. This historical identity should be reconciled before attributing investment records or prior transactions to the new fund. Baillie Gifford's official legal disclosures also identify six separately organized Private Growth Opportunity funds with distinct general partner arrangements. These vehicles may create different contractual rights and economic exposures, even where they share a broader investment management platform. The central investor concerns involve incomplete initial fundraising, private company valuation uncertainty, affiliated investment allocation, fee transparency and limited liquidity. The sponsor's institutional investment experience provides relevant background but does not establish Fund No. 1's portfolio, audited performance or recoverable investment value.

Baillie Gifford Private Growth Opportunity Fund (No. 1) L.P. · CIK 0002135970Read article →
Morey Mercantile SEC Review 2026: $5M Offering, Property Debt and Investor Risks
INDEPENDENT RESEARCH

Morey Mercantile SEC Review 2026: $5M Offering, Property Debt and Investor Risks

Morey Mercantile, LLC is a Colorado commercial real estate investment entity associated with Mercantile Square, a historic mixed-use property in downtown Denver. Its September 2026 Form D filing reports a completed $5 million equity offering, while earlier SEC records reveal debt financing extending back to 2014. Unlike a newly established property investment vehicle relying solely on proposed development plans, Morey Mercantile has an identifiable real estate operating history, documented participation in a major urban redevelopment project and a recent commercial lease involving Denver Summit FC. Nevertheless, the latest equity financing should not be interpreted as proof of unrestricted liquidity, an independently verified property valuation or the absence of existing financial obligations. The issuer's historical securities disclosures include substantial debt offerings, while its connections to the broader Coughlin real estate organization introduce important questions concerning management fees, related-party arrangements and the allocation of economic interests. Mercantile Square's historic-building characteristics also create potential exposure to maintenance expenditure, tenant turnover, insurance costs and changing downtown office and retail demand. Investors should distinguish the underlying property's documented commercial activity from the actual rights attached to securities issued by Morey Mercantile. The central investment question is whether current property income, financing obligations and capital expenditure requirements support the economics of the September 2026 offering.

Morey Mercantile · CIK 0001599488Read article →
Public Pension Capital SEC Review 2026: $2.17B Form D, PPC Enterprises and Investment Risks
INDEPENDENT RESEARCH

Public Pension Capital SEC Review 2026: $2.17B Form D, PPC Enterprises and Investment Risks

Public Pension Capital, LLC is a Delaware private equity investment entity associated with PPC Enterprises, an established New York investment management platform specializing in middle-market businesses. Its September 24, 2026 Form D amendment reports approximately $2.17 billion in cumulative securities sales, representing an increase of $245 million from the previous year's filing. Unlike newly organized private funds with limited operating histories, Public Pension Capital has maintained a regulatory filing record since 2014 and operates within a management platform with identifiable leadership, institutional investors and a documented portfolio of operating businesses. PPC focuses on industrial services, business and financial services, and healthcare services, using a long-term ownership strategy intended to support operational development and enterprise value creation. Nevertheless, the substantial cumulative fundraising figure should not be confused with current net asset value, realized investment profits or capital immediately available for distribution. The fund's long operating history also introduces questions concerning historical investment valuations, capital recycling, portfolio concentration and the treatment of older investments. Investors should distinguish the manager's institutional background from the actual economic rights and financial performance attributable to Public Pension Capital itself.

Public Pension Capital, LLC · CIK 0001609477Read article →
Tru Arrow Technology Partners II SEC Review: $110.7M Raise, Fees and Offshore Fund Risks
INDEPENDENT RESEARCH

Tru Arrow Technology Partners II SEC Review: $110.7M Raise, Fees and Offshore Fund Risks

Tru Arrow Technology Partners II, LP is a Delaware venture capital investment vehicle associated with Tru Arrow Management and investor Glenn Fuhrman. Its September 23, 2026 amended Form D reports $110.67 million in cumulative securities sold to 62 investors, compared with $74.27 million and 47 investors in its original September 2025 filing. The increase establishes a documented expansion in reported fundraising, but it does not establish current net asset value, realized profits or the amount of capital already deployed into technology companies. The fund's structure deserves particular attention because a separately registered Cayman Islands vehicle, Tru Arrow Technology Partners Offshore II, operates alongside the US partnership and identifies the same investment manager and general partner. The available records do not establish whether their assets are completely overlapping, independently allocated or held through a common investment structure. A further financial concern appears in the fund's own regulatory disclosures: although related-person payments and sales commissions are reported as zero, the investment manager expressly receives customary management fees. The principal due-diligence issues therefore concern fund-level performance, domestic and offshore vehicle relationships, investment allocation, fee transparency and the valuation of potentially illiquid technology investments. These documented questions do not establish fraud or regulatory misconduct, but they require more detailed contractual and financial evidence than Form D provides.

Tru Arrow Technology Partners II, LP · CIK 0002086380Read article →
Aromha SEC Review 2026: Brain Health Test, FDA Status and Funding Risks
INDEPENDENT RESEARCH

Aromha SEC Review 2026: Brain Health Test, FDA Status and Funding Risks

Aromha, Inc. is a Delaware healthcare technology company developing an at-home olfactory screening platform intended to identify changes in smell function that may be associated with cognitive impairment and neurodegenerative disease. Its corporate identity is supported by SEC filings under CIK 0002047430, while its scientific foundation includes a peer-reviewed 2025 study involving researchers from Massachusetts General Hospital and Harvard Medical School. These records distinguish Aromha from a business relying entirely on unsupported medical marketing claims. Nevertheless, its September 2026 financing and clinical positioning reveal several material issues requiring closer examination. The latest Form D reports only $75,000 sold to one investor, while earlier filings identify separate financing activity, including a $3 million offering that had recorded just $250,000 in sales at its October 2025 filing date. The company also declined to disclose its revenue range, limiting public assessment of commercial adoption and financial sustainability. More importantly, the Aromha Brain Health Test is presented as an FDA-registered, 510(k)-exempt medical device for screening olfactory loss, not an FDA-approved diagnostic test for Alzheimer's disease. Its published research supports investigation of olfactory biomarkers but does not establish reliable prediction of future dementia across the general population. Investors should distinguish genuine research activity, medical-device registration and historical research grants from independently demonstrated clinical utility, recurring commercial revenue and sustainable investment value.

Aromha · CIK 0002047430Read article →